LONG-TERM EFFECTS OF ETANERCEPT AND CERTOLIZUMAB PEGOL TREATMENT ON VASCULAR FUNCTION AND LIPID PARAMETERS IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS

被引：2
|
作者：
Vegh, Edit [1 ]
Vancsa, Andrea [1 ,2 ]
Kerekes, Gyoergy
Balazs, Fruzsina [1 ]
Pogacsas, Lilla [1 ]
Bodnar, Nora [1 ]
Szuecs, Gabriella [1 ]
Szanto, Sandor [1 ]
Szekanecz, Zoltan [1 ]
机构：
[1] Univ Debrecen, Med & Hlth Sci Ctr, Inst Med, Dept Rheumatol, H-4012 Debrecen, Hungary
[2] Univ Debrecen, Dept Angiol, H-4012 Debrecen, Hungary
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2013-205124.82
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A1.83
引用
收藏
页码：A36 / A37
页数：6
相关论文
共 50 条
  • [21] LONG-TERM WORKING ABILITY IN PATIENTS WITH RHEUMATOID-ARTHRITIS AND ANKYLOSING-SPONDYLITIS
    BRATTSTROM, M
    LARSSON, BM
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1982, : 26 - 26
  • [22] LONG-TERM TRIAL OF A HIGHER DOSE OF NAPROXEN IN THE TREATMENT OF RHEUMATOID-ARTHRITIS, ANKYLOSING-SPONDYLITIS AND OSTEOARTHRITIS
    HAZLEMAN, BL
    MOWAT, AG
    STURGE, RA
    HALL, M
    SEIFERT, MH
    LIYANAGE, SP
    MATHEWS, JA
    JENNER, JR
    ENGLER, C
    EUROPEAN JOURNAL OF RHEUMATOLOGY AND INFLAMMATION, 1979, 2 (01) : 56 - 64
  • [23] Combination therapy with certolizumab pegol plus methotrexate maintains long-term efficacy in the treatment of rheumatoid arthritis: A 2-year analysis
    Keystone, Edward C.
    Schiff, Michael H.
    Mease, Philip
    van Vollenhoven, Ronald F.
    Desai, Chintu
    Smolen, Josef
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S529 - S529
  • [24] Clinical Utility and Factors Associated with Certolizumab Pegol Drug Levels and Anti-Drug Antibodies in the Long-Term Treatment of Rheumatoid Arthritis
    Jani, Meghna
    Chinoy, Hector
    Isaacs, John
    Morgan, Ann W.
    Wilson, Anthony
    Hyrich, Kimme L.
    Plant, Darren
    Barton, Anne
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [25] Combination Therapy with Certolizumab Pegol Plus Methotrexate Maintains Long-term Efficacy in the Treatment of Rheumatoid Arthritis: A 2-year Analysis
    Haraoui, Paul
    Keystone, Edward
    Schiff, Michael
    Mease, Philip
    van Vollenhoven, Ronald F.
    Desai, Chintu
    Smolen, Josef
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2572 - 2572
  • [26] Multiple Approaches for Implementation of Long-Term Efficacy: Interpretation of Certolizumab Pegol Data in Rheumatoid Arthritis Case Study.
    Keystone, Edward C.
    Smolen, Josef S.
    Strand, Vibeke
    Kumke, Thomas
    Mountian, Irina
    Walker, Susan
    Landewe, Robert B. M.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1080 - S1080
  • [27] Improvement in Disease Activity and the Long-Term Risk of Serious Infectious Events in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
    Curtis, Jeffrey R.
    de Longueville, Marc
    O'Brien, Cathy
    Haraoui, Boulos
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [28] Etanercept:: long-term clinical experience in rheumatoid arthritis and other arthritis
    Cobo-Ibanez, T.
    Martin-Mola, E.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (09) : 1373 - 1397
  • [29] The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
    Fleischmann, Roy
    OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2009, 1 : 95 - 106
  • [30] Safety of etanercept treatment in patients with hepatitis B or C virus, and rheumatoid arthritis or ankylosing spondylitis
    Moreno, E
    Erra, A
    Leon, Y
    Tomás, C
    Barceló, P
    Marsal, S
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 280 - 280
12345